New Cluster for Nucleic Acid-based Therapeutics in Munich

The winners of the second round of the Clusters4Future competition in Germany have been announced by the German Federal Ministry of Education and Research (BMBF). Among them is C-NATM, a cluster focused on the development of innovative therapies using nucleic acids. C-NATM is led by Prof. Thomas Carell, Director of the Institute of Chemical Epigenetics at LMU Munich and Supervisor of two ESRs in NATURE-ETN. The cluster involves the two universities in Munich, the Helmholtz Center for Health Research, and various international and biotech companies based in the Munich area.

The main objective of C-NATM is to create ground-breaking therapeutics using DNA, RNA, and smaller nucleic acids. An example of this is the development of RNA-based vaccines for combating COVID-19, although the potential of these technologies extends far beyond that, potentially opening up a new era in drug therapy.

The Cluster will receive five million euros funding annually from the German government, the Free State of Bavaria, and participating companies.